Table 3.
Outcomes 30 days
| Clopidogrel | Ticagrelor | p value | |
|---|---|---|---|
| (n = 577) | (n = 426) | ||
| Any Bleeding | 132 (22.9) | 93 (21.8) | 0.70 |
| TIMI minimal | 79 (13.7) | 52 (12.2) | 0.78* |
| TIMI minor | 53 (9.2) | 41 (9.6) | |
| TIMI major | 0 (0.0) | 0 (0.0) | |
| BARC type 1 | 79 (13.7) | 52 (12.2) | 0.91** |
| BARC type 2 | 52 (9.0) | 40 (9.4) | |
| BARC type 3a+3b | 1 (0.2) | 1 (0.2) | |
| BARC type 4+5 | 0 (0.0) | 0 (0.0) | |
| Bleeding localization | |||
| Arterial access site | 128 (97.0) | 91 (97.8) | 0.23 |
| Urogenital | 0 (0.0) | 1 (1.1) | |
| Nasal | 3 (2.3) | 0 (0.0) | |
| Intramuscular | 1 (0.8) | 0 (0.0) | |
| Pericardial | 0 (0.0) | 1 (1.1) | |
| MACE 30 days | 7 (1.2) | 10 (2.3) | 0.17 |
| MI | 6 (1.0) | 10 (2.3) | 0.28 |
| Periprocedural MI | 6 (1.0) | 8 (1.9) | 0.26 |
| ST | 0 (0.0) | 1 (0.2) | 0.43 |
| Stroke | 1 (0.2) | 0 (0.0) | 1.0 |
| Death | 0 (0.0) | 0 (0.0) | N/A |
Results are presented as numbers and (percentages). TIMI, thrombolysis in myocardial infarction; BARC, Bleeding Academic Research Consortium; MACE, major adverse cardiovascular events (includes death, stent thrombosis, MI and stroke within 30 days); MI, myocardial infarction.
*
Statistical test for all TIMI bleedings.
**
Statistical test for all BARC bleedings.